Biblio

Export 2215 results:
Author Title Type Year
Filters: First Letter Of Keyword is A  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
AC133 Antigen
R. Yu, Deochand, C., Krotow, A., Leão, R., Tong, M., Agarwal, A. R., Cadenas, E., and de la Monte, S. M., “Tobacco Smoke-Induced Brain White Matter Myelin Dysfunction: Potential Co-Factor Role of Smoking in Neurodegeneration.”, J Alzheimers Dis, vol. 50, no. 1, pp. 133-48, 2016.
Acetamides
J. Min Song, Sung, Y. Me, Nam, J. Han, Yoon, H., Chung, A., Moffat, E., Jung, M., Pak, D. T. S., Kim, J., and Hoe, H. - S., “A Mercaptoacetamide-Based Class II Histone Deacetylase Inhibitor Increases Dendritic Spine Density via RasGRF1/ERK Pathway.”, J Alzheimers Dis, vol. 51, no. 2, pp. 591-604, 2016.
Acetylation
J. Gräff, Rei, D., Guan, J. - S., Wang, W. - Y., Seo, J., Hennig, K. M., Nieland, T. J. F., Fass, D. M., Kao, P. F., Kahn, M., Su, S. C., Samiei, A., Joseph, N., Haggarty, S. J., Delalle, I., and Tsai, L. - H., “An epigenetic blockade of cognitive functions in the neurodegenerating brain.”, Nature, vol. 483, no. 7388, pp. 222-6, 2012.
A. Tramutola, Pupo, G., Di Domenico, F., Barone, E., Arena, A., Lanzillotta, C., Broekaart, D., Blarzino, C., Head, E., D Butterfield, A., and Perluigi, M., “Activation of p53 in Down Syndrome and in the Ts65Dn Mouse Brain is Associated with a Pro-Apoptotic Phenotype.”, J Alzheimers Dis, vol. 52, no. 1, pp. 359-71, 2016.
Acetylcholinesterase
D. Dingova, Fazekas, T., Okuliarova, P., Strbova, J., Kucera, M., and Hrabovska, A., “Low Plasma Cholinesterase Activities are Associated with Deficits in Spatial Orientation, Reduced Ability to Perform Basic Activities of Daily Living, and Low Body Mass Index in Patients with Progressed Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 3, pp. 801-13, 2016.
D. E. Moss, Perez, R. G., and Kobayashi, H., “Cholinesterase Inhibitor Therapy in Alzheimer's Disease: The Limits and Tolerability of Irreversible CNS-Selective Acetylcholinesterase Inhibition in Primates.”, J Alzheimers Dis, vol. 55, no. 3, pp. 1285-1294, 2017.
Acetylcysteine
H. - H. Tsou, Hsu, W. - C., Fuh, J. - L., Chen, S. - P., Liu, T. - Y., and Wang, H. - T., “Alterations in Acrolein Metabolism Contribute to Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 2, pp. 571-580, 2018.
Acoustics
C. Themistocleous, Ficek, B., Webster, K., Ouden, D. - Bden, Hillis, A. E., and Tsapkini, K., “Automatic Subtyping of Individuals with Primary Progressive Aphasia.”, J Alzheimers Dis, vol. 79, no. 3, pp. 1185-1194, 2021.
Acrolein
A. Belkacemi and Ramassamy, C., “Anthocyanins Protect SK-N-SH Cells Against Acrolein-Induced Toxicity by Preserving the Cellular Redox State.”, J Alzheimers Dis, vol. 50, no. 4, pp. 981-98, 2016.
H. - H. Tsou, Hsu, W. - C., Fuh, J. - L., Chen, S. - P., Liu, T. - Y., and Wang, H. - T., “Alterations in Acrolein Metabolism Contribute to Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 2, pp. 571-580, 2018.
Acrylamides
S. Shi, Liang, D., Bao, M., Xie, Y., Xu, W., Wang, L., Wang, Z., and Qiao, Z., “Gx-50 Inhibits Neuroinflammation via α7 nAChR Activation of the JAK2/STAT3 and PI3K/AKT Pathways.”, J Alzheimers Dis, vol. 50, no. 3, pp. 859-71, 2016.
N. E. Gray, Zweig, J. A., Kawamoto, C., Quinn, J. F., and Copenhaver, P. F., “STX, a Novel Membrane Estrogen Receptor Ligand, Protects Against Amyloid-β Toxicity.”, J Alzheimers Dis, vol. 51, no. 2, pp. 391-403, 2016.
K. Krishna, Behnisch, T., and Sajikumar, S., “Inhibition of Histone Deacetylase 3 Restores Amyloid-β Oligomer-Induced Plasticity Deficit in Hippocampal CA1 Pyramidal Neurons.”, J Alzheimers Dis, vol. 51, no. 3, pp. 783-91, 2016.
Action Potentials
M. Wang, Gamo, N. J., Yang, Y., Jin, L. E., Wang, X. - J., Laubach, M., Mazer, J. A., Lee, D., and Arnsten, A. F. T., “Neuronal basis of age-related working memory decline.”, Nature, vol. 476, no. 7359, pp. 210-3, 2011.
Activities of Daily Living
A. Koppara, Wolfsgruber, S., Kleineidam, L., Schmidtke, K., Frölich, L., Kurz, A., Schulz, S., Hampel, H., Heuser, I., Peters, O., Reischies, F. M., Jahn, H., Luckhaus, C., Hüll, M., Gertz, H. - J., Schröder, J., Pantel, J., Rienhoff, O., Rüther, E., Henn, F., Wiltfang, J., Maier, W., Jessen, F., Kornhuber, J., and Wagner, M., “The Latent Dementia Phenotype δ is Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 49, no. 2, pp. 547-60, 2016.
K. Hoffmann, Sobol, N. A., Frederiksen, K. S., Beyer, N., Vogel, A., Vestergaard, K., Brændgaard, H., Gottrup, H., Lolk, A., Wermuth, L., Jacobsen, S., Laugesen, L. P., Gergelyffy, R. G., Høgh, P., Bjerregaard, E., Andersen, B. B., Siersma, V., Johannsen, P., Cotman, C. W., Waldemar, G., and Hasselbalch, S. G., “Moderate-to-High Intensity Physical Exercise in Patients with Alzheimer's Disease: A Randomized Controlled Trial.”, J Alzheimers Dis, vol. 50, no. 2, pp. 443-53, 2016.
C. E. Fischer, Qian, W., Schweizer, T. A., Millikin, C. P., Ismail, Z., Smith, E. E., Lix, L. M., Shelton, P., and Munoz, D. G., “Lewy Bodies, Vascular Risk Factors, and Subcortical Arteriosclerotic Leukoencephalopathy, but not Alzheimer Pathology, are Associated with Development of Psychosis in Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 1, pp. 283-95, 2016.
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R., “Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
G. W. Rebok, Ball, K., Guey, L. T., Jones, R. N., Kim, H. - Y., King, J. W., Marsiske, M., Morris, J. N., Tennstedt, S. L., Unverzagt, F. W., and Willis, S. L., “Ten-year effects of the advanced cognitive training for independent and vital elderly cognitive training trial on cognition and everyday functioning in older adults.”, J Am Geriatr Soc, vol. 62, no. 1, pp. 16-24, 2014.
D. Dingova, Fazekas, T., Okuliarova, P., Strbova, J., Kucera, M., and Hrabovska, A., “Low Plasma Cholinesterase Activities are Associated with Deficits in Spatial Orientation, Reduced Ability to Perform Basic Activities of Daily Living, and Low Body Mass Index in Patients with Progressed Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 3, pp. 801-13, 2016.
D. R. Royall, Palmer, R. F., Matsuoka, T., Kato, Y., Taniguchi, S., Ogawa, M., Fujimoto, H., Okamura, A., Shibata, K., Nakamura, K., Nakaaki, S., Koumi, H., Mimura, M., Fukui, K., and Narumoto, J., “Greater than the Sum of Its Parts: δ can be Constructed from Item Level Data.”, J Alzheimers Dis, vol. 49, no. 2, pp. 571-9, 2016.
D. R. Royall, Palmer, R. F., Matsuoka, T., Kato, Y., Taniguchi, S., Ogawa, M., Fujimoto, H., Okamura, A., Shibata, K., Nakamura, K., Nakaaki, S., Koumi, H., Mimura, M., Fukui, K., and Narumoto, J., “δ Scores are Exportable Across Cultural and Linguistic Boundaries.”, J Alzheimers Dis, vol. 49, no. 2, pp. 561-70, 2016.
B. Yoon, Shim, Y. S., Park, H. - K., Park, S. Ah, Choi, S. Hye, and Yang, D. Won, “Predictive factors for disease progression in patients with early-onset Alzheimer's disease.”, J Alzheimers Dis, vol. 49, no. 1, pp. 85-91, 2016.
C. Pimouguet, Le-Goff, M., Rizzuto, D., Berr, C., Leffondré, K., Pérès, K., Dartigues, J. François, and Helmer, C., “Effect of Early Referral to Specialist in Dementia on Institutionalization and Functional Decline: Findings from a Population-Based Study.”, J Alzheimers Dis, vol. 49, no. 3, pp. 819-28, 2016.
E. Stogmann, Moser, D., Klug, S., Gleiss, A., Auff, E., Dal-Bianco, P., Pusswald, G., and Lehrner, J., “Activities of Daily Living and Depressive Symptoms in Patients with Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1043-50, 2016.

Pages